177Lu-FAP-2286 Radioligand Therapy in End-Stage Metastatic Cancer: a promising theranostic approach
This single-center retrospective study demonstrates that 177Lu-FAP-2286 radioligand therapy is a feasible and relatively safe treatment option for end-stage metastatic cancer patients who have exhausted standard therapies, offering meaningful disease control and survival benefits while highlighting baseline 68Ga-FAP-2286 PET/CT parameters as independent prognostic factors.